JP2019506412A - 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗−ＬＡＭおよび抗−ＰＩＭ６／ＬＡＭモノクローナル抗体 - Google Patents

結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗−ＬＡＭおよび抗−ＰＩＭ６／ＬＡＭモノクローナル抗体 Download PDF

Info

Publication number
JP2019506412A
JP2019506412A JP2018541386A JP2018541386A JP2019506412A JP 2019506412 A JP2019506412 A JP 2019506412A JP 2018541386 A JP2018541386 A JP 2018541386A JP 2018541386 A JP2018541386 A JP 2018541386A JP 2019506412 A JP2019506412 A JP 2019506412A
Authority
JP
Japan
Prior art keywords
lam
antibody
seq
antigen
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018541386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506412A5 (enExample
Inventor
ピンター，アブラハム
パテル，ディーンダヤル
チョードリー，アロック
Original Assignee
ラトガース， ザ ステイト ユニバーシティー オブ ニュージャージー
ラトガース， ザ ステイト ユニバーシティー オブ ニュージャージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラトガース， ザ ステイト ユニバーシティー オブ ニュージャージー, ラトガース， ザ ステイト ユニバーシティー オブ ニュージャージー filed Critical ラトガース， ザ ステイト ユニバーシティー オブ ニュージャージー
Publication of JP2019506412A publication Critical patent/JP2019506412A/ja
Publication of JP2019506412A5 publication Critical patent/JP2019506412A5/ja
Priority to JP2021063301A priority Critical patent/JP7316685B2/ja
Priority to JP2023031004A priority patent/JP2023075196A/ja
Priority to JP2024137825A priority patent/JP2024174883A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
JP2018541386A 2016-02-10 2017-02-01 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗−ＬＡＭおよび抗−ＰＩＭ６／ＬＡＭモノクローナル抗体 Pending JP2019506412A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021063301A JP7316685B2 (ja) 2016-02-10 2021-04-02 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体
JP2023031004A JP2023075196A (ja) 2016-02-10 2023-03-01 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体
JP2024137825A JP2024174883A (ja) 2016-02-10 2024-08-19 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662293406P 2016-02-10 2016-02-10
US62/293,406 2016-02-10
PCT/US2017/016058 WO2017139153A1 (en) 2016-02-10 2017-02-01 Novel anti-lam and anti-pim6/lam monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021063301A Division JP7316685B2 (ja) 2016-02-10 2021-04-02 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体

Publications (2)

Publication Number Publication Date
JP2019506412A true JP2019506412A (ja) 2019-03-07
JP2019506412A5 JP2019506412A5 (enExample) 2020-03-12

Family

ID=59563993

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018541386A Pending JP2019506412A (ja) 2016-02-10 2017-02-01 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗−ＬＡＭおよび抗−ＰＩＭ６／ＬＡＭモノクローナル抗体
JP2021063301A Active JP7316685B2 (ja) 2016-02-10 2021-04-02 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体
JP2023031004A Pending JP2023075196A (ja) 2016-02-10 2023-03-01 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体
JP2024137825A Pending JP2024174883A (ja) 2016-02-10 2024-08-19 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021063301A Active JP7316685B2 (ja) 2016-02-10 2021-04-02 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体
JP2023031004A Pending JP2023075196A (ja) 2016-02-10 2023-03-01 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体
JP2024137825A Pending JP2024174883A (ja) 2016-02-10 2024-08-19 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体

Country Status (10)

Country Link
US (4) US10729771B2 (enExample)
EP (2) EP4299072A3 (enExample)
JP (4) JP2019506412A (enExample)
CN (2) CN110092830B (enExample)
AU (2) AU2017218415B2 (enExample)
CA (1) CA3013904C (enExample)
ES (1) ES2970828T3 (enExample)
RU (1) RU2732502C2 (enExample)
WO (1) WO2017139153A1 (enExample)
ZA (3) ZA201805990B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2732502C2 (ru) 2016-02-10 2020-09-18 Ратгерс, Де Стейт Юниверсити Оф Нью Джерси Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis
US10830760B2 (en) 2017-12-20 2020-11-10 General Electric Company Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity
JP2021521462A (ja) * 2018-03-29 2021-08-26 ファウンデーション オブ イノベーティブ ニュー ダイアグノスティクス 抗体または抗体の組み合わせおよび対象の尿試料中のマイコバクテリウム関連抗原の検出のためのその使用
EP3823670A4 (en) * 2018-07-19 2022-04-20 Rutgers, the State University of New Jersey METHODS FOR DUAL DETECTION AND DIFFERENTIATION OF INFECTIONS WITH MYCOBACTERIUM TUBERCULOSIS COMPLEX AND NON-TUBERCULOUS MYCOBACTERIA
EP3845903A4 (en) 2018-08-31 2021-11-24 FUJIFILM Corporation IMMUNOCHROMATOGRAPHY KIT AND METHOD FOR DETECTION OF MYCOBACTERIUM TUBERCULOSIS
EP4040155B1 (en) 2019-09-30 2024-11-27 FUJIFILM Corporation Immunochromatography
EP4040151B1 (en) 2019-09-30 2025-08-13 FUJIFILM Corporation Immunological test method
CN111337665A (zh) * 2020-01-16 2020-06-26 卢氏实验室公司 一种用于检测肺结核感染的免疫层析试纸条及其制备方法
JP7740995B2 (ja) 2020-01-31 2025-09-17 富士フイルム株式会社 免疫検査方法
EP4099013A4 (en) 2020-01-31 2023-02-15 FUJIFILM Corporation IMMUNOCHROMATOGRAPHY
JP7350100B2 (ja) 2020-01-31 2023-09-25 富士フイルム株式会社 イムノクロマトグラフィー
CN111153992A (zh) * 2020-02-21 2020-05-15 首都医科大学附属北京胸科医院 结核分枝杆菌lam的单克隆抗体及其用途
US20230258633A1 (en) * 2020-07-07 2023-08-17 The Regents Of The University Of California Method for antigen detection from direct clinical samples
CN116669707B (zh) * 2020-08-05 2025-11-14 杜兰教育基金管理委员会 体液样品中结核的检测方法
EP4212873A4 (en) 2020-09-11 2024-06-05 FUJIFILM Corporation CONCENTRATION DEVICE, METHOD FOR CONCENTRATING A SAMPLE SOLUTION, METHOD FOR TESTING A SAMPLE SOLUTION AND TEST KIT
WO2022054524A1 (ja) 2020-09-11 2022-03-17 富士フイルム株式会社 濃縮デバイス、検体液の濃縮方法、検体液の検査方法、及び、検査キット
EP4212876B1 (en) 2020-09-11 2025-05-14 FUJIFILM Corporation Liquid specimen concentration method, and liquid specimen inspection method
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
EP4263598A4 (en) * 2020-12-15 2025-04-09 Albert Einstein College of Medicine High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibodies
CN113480659B (zh) * 2021-06-30 2022-10-21 迪比康(上海)生物科技有限公司 人源抗结核分枝杆菌复合群lam单克隆抗体及其制备和应用
CN114984870A (zh) * 2022-03-15 2022-09-02 齐欣 一种重组蛋白质微球及其制备方法和应用
CN117247450B (zh) * 2023-10-10 2025-02-25 广州市雷德生物科技有限公司 一种lam抗体及其应用
CN118178640B (zh) * 2024-03-08 2025-11-21 中国农业大学 含有牛分枝杆菌表面多糖的佐剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507544A (ja) * 2004-07-20 2008-03-13 キーモゲン インコーポレイテッド マイコバクテリア感染検出用濃縮抗体、使用方法、及びそれを使用する診断検査
WO2012102679A1 (en) * 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2013129634A1 (ja) * 2012-02-29 2013-09-06 大塚製薬株式会社 抗リポアラビノマンナン抗体及び当該抗体を用いた抗酸菌症のイムノアッセイ

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
EP0729353B2 (en) 1993-11-19 2012-09-12 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US20010007660A1 (en) * 1997-06-04 2001-07-12 Aharona Glatman-Freedman Methods of treating and protecting against tuberculosis using a monoclonal antibody selective for mycobacterium tuberculosis
US6573238B2 (en) 1997-11-07 2003-06-03 Chiron Corporation Method for producing sustained-release formulations
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
AU2002248792B2 (en) 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US7063725B2 (en) 2002-10-21 2006-06-20 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20050187631A1 (en) 2004-01-27 2005-08-25 Sdgi Holdings, Inc. Prosthetic device
CN101216491B (zh) * 2008-01-08 2012-06-06 广州益善生物技术有限公司 结核分枝杆菌检测液相芯片及其制备方法
WO2009105150A2 (en) * 2008-01-28 2009-08-27 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
KR20110057245A (ko) 2008-09-19 2011-05-31 메디뮨 엘엘씨 Ｃｄ105에 대해 지시된 항체 및 그의 용도
WO2011013698A1 (ja) * 2009-07-29 2011-02-03 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
RU2732502C2 (ru) 2016-02-10 2020-09-18 Ратгерс, Де Стейт Юниверсити Оф Нью Джерси Новые моноклональные антитела к LAM и PIM6/LAM для диагностики и лечения инфекций, вызванных Mycobacterium tuberculosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507544A (ja) * 2004-07-20 2008-03-13 キーモゲン インコーポレイテッド マイコバクテリア感染検出用濃縮抗体、使用方法、及びそれを使用する診断検査
WO2012102679A1 (en) * 2011-01-24 2012-08-02 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2013129634A1 (ja) * 2012-02-29 2013-09-06 大塚製薬株式会社 抗リポアラビノマンナン抗体及び当該抗体を用いた抗酸菌症のイムノアッセイ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J INFECT DEV CTRIES(2010) 4(2):096-102, JPN6020050858, ISSN: 0004419735 *

Also Published As

Publication number Publication date
JP2023075196A (ja) 2023-05-30
CN110092830B (zh) 2023-07-04
US11707525B2 (en) 2023-07-25
RU2018131622A (ru) 2020-03-10
BR112018016226A8 (pt) 2023-10-24
AU2024205286A1 (en) 2024-08-22
US20200316199A1 (en) 2020-10-08
EP3414573B1 (en) 2023-11-08
EP4299072A3 (en) 2024-05-01
JP2021105034A (ja) 2021-07-26
RU2732502C2 (ru) 2020-09-18
ZA201805990B (en) 2023-01-25
BR112018016226A2 (pt) 2019-01-02
US11273220B2 (en) 2022-03-15
AU2017218415A1 (en) 2018-09-27
WO2017139153A1 (en) 2017-08-17
ES2970828T3 (es) 2024-05-30
US20220168420A1 (en) 2022-06-02
ZA202307912B (en) 2025-11-26
EP3414573A1 (en) 2018-12-19
AU2017218415B2 (en) 2024-05-02
JP7316685B2 (ja) 2023-07-28
US12303562B2 (en) 2025-05-20
CN110092830A (zh) 2019-08-06
RU2018131622A3 (enExample) 2020-04-13
US10729771B2 (en) 2020-08-04
ZA202209045B (en) 2023-12-20
EP4299072A2 (en) 2024-01-03
US20240307535A1 (en) 2024-09-19
US20190038747A1 (en) 2019-02-07
CN109073649A (zh) 2018-12-21
CA3013904A1 (en) 2017-08-17
CA3013904C (en) 2023-12-12
EP3414573A4 (en) 2019-10-30
JP2024174883A (ja) 2024-12-17

Similar Documents

Publication Publication Date Title
JP7316685B2 (ja) 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｔｕｂｅｒｃｕｌｏｓｉｓ）感染の診断および治療のための新規な抗－ＬＡＭおよび抗－ＰＩＭ６／ＬＡＭモノクローナル抗体
JP2016507470A (ja) Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
JPH08510909A (ja) Ｃｄ１４媒介細胞活性化を抑制するための方法および組成物
KR20120128688A (ko) 녹농균의 혈청형 ｉ 지질다당류에 대한 항체
JP6560195B2 (ja) 黄色ブドウ球菌のＬｕｋＧＨ（ＬｕｋＡＢ）毒素を中和する、非常に強力な抗体の生成
TW202126684A (zh) 抗α-溶血素的抗體及其應用
WO2021237717A1 (zh) 抗cldn18.2和cd3的双特异性抗体
CN112969711B (zh) 使用克拉扎珠单抗脱敏和改善hla致敏患者中的肾脏移植
JP7368670B2 (ja) 破傷風毒素に対する完全天然型ヒト中和モノクロナル抗体及びその応用
JP2022502508A (ja) 抗ｃｄ３０抗体薬物複合体療法を使用して末梢性ｔ細胞リンパ腫を処置する方法
CN113194996A (zh) 克拉扎珠单抗用于治疗慢性抗体介导的器官移植物排斥反应
JP2007515394A (ja) ドメイン交換結合分子、その使用方法および製造方法
BR112018016226B1 (pt) Anticorpo antilipoarabinomanana (anti-lam) monoclonal, kit para detectar um epítopo de lam, método in vitro para diagnosticar uma infecção de tuberculose ativa em um indivíduo e método in vitro de pré-concentração de lam a partir de uma amostra biológica
CN118440196A (zh) 抗il1r2的抗体、其抗原结合片段及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210824